首页> 美国卫生研究院文献>Current Health Sciences Journal >Study of Nimesulide Release from Solid Pharmaceutical Formulations in Tween 80 Solutions
【2h】

Study of Nimesulide Release from Solid Pharmaceutical Formulations in Tween 80 Solutions

机译:吐温80溶液中固体药物制剂中尼美舒利释放的研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Nimesulide is a weakly acidic non-steroidal anti-inflammatory drug (NSAIDs). Like many non-steroidal anti-inflammatory drugs, Nimesulide is very sparingly soluble in water (≈ 0.01 mg/mL).The poor aqueous solubility and wettability of Nimesulide gives rise to difficulties in pharmaceutical formulations for oral or parenteral delivery, which may lead to variable bioavailability. Based on the Biopharmaceutical Classification System (BCS), Nimesulide is considered a BCS 2 drug (poorly soluble and highly permeable). Solubilization in surfactant solutions above critical micelle concentration (CMC) offers one approach to the formulation of poorly soluble drugs. Weakly acidic and basic drugs may be brought into solution by the solubilizing action of surfactants. In this study, different concentrations of Tween 80 was used in combination with buffer (pH 7.4) to increase the solubility of Nimesulide. The results show that the dependence of the released amount on the Tween concentration is not linear, very low Tween concentration showing a decrease of “solubility“, probably connected to a critical micelle concentration at the interface Nimesulide solution. An “analytical” artefact connected to a decreasing ultraviolet absorption of Nimesulide because of Nimesulide precipitation, the formation of a colloidal solution is possible, and the phenomenon remains to be searched further. It is hard to explain that for an almost complete solubilization a significant Tween quantity is necessary and this should be more than that of other slightly soluble drugs.
机译:尼美舒利是一种弱酸性非甾体抗炎药(NSAIDs)。与许多非甾体类抗炎药一样,尼美舒利在水中的溶解度非常低(≈0.01 mg / mL),尼美舒利的不良水溶性和润湿性给口服或肠胃外给药的药物制剂带来困难。可变的生物利用度。基于生物制药分类系统(BCS),尼美舒利被视为BCS 2药物(难溶和高渗透性)。在高于临界胶束浓度(CMC)的表面活性剂溶液中增溶提供了一种配制难溶性药物的方法。弱酸性和碱性药物可通过表面活性剂的增溶作用进入溶液。在这项研究中,将不同浓度的吐温80与缓冲液(pH 7.4)结合使用以增加尼美舒利的溶解度。结果表明,释放量对吐温浓度的依赖性不是线性的,非常低的吐温浓度显示“溶解度”降低,可能与尼美舒利溶液界面上的临界胶束浓度有关。由于尼美舒利的沉淀,与尼美舒利的紫外线吸收减少有关的“分析”伪像,可能形成胶体溶液,这种现象仍有待进一步研究。难以解释的是,对于几乎完全溶解而言,大量吐温是必要的,并且它应该比其他微溶性药物要多。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号